Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - USD ($)	Total	Public Offering [Member]	Series B Redeemable Convertible Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Public Offering [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Public Offering [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance at Dec. 31, 2016	$ 32,207,323				$ 24		$ 71,035,567		$ (31,259,449)	$ (7,574,812)
Beginning Balance (in shares) at Dec. 31, 2016					235,615
Beginning Balance at Dec. 31, 2016				$ 5,993
Beginning Balance (in shares) at Dec. 31, 2016				599,285
Stock based compensation	1,210,499						1,210,499
Vesting and accelerated vesting of restricted stock	233,679						233,679
Vesting and accelerated vesting of restricted stock (in shares)					1,704
Exercises of stock options	16,455				$ 1		16,454
Exercises of stock options (in shares)					6,689
Warrant issuance, net of issuance costs	548,956						548,956
Conversion of Series B convertible preferred stock into common stock				$ (5,993)	$ 2		5,991
Conversion of Series B convertible preferred stock into common stock (in shares)				(599,285)	19,976
Conversion of convertible notes and accrued interest into common stock	3,645,424				$ 1		3,645,423
Conversion of convertible notes and accrued interest into common stock (in shares)					10,558
Warrant exercises					$ 2		(2)
Warrant exercises (in shares)					22,024
Issuance of common stock for the acquisition of subsidiaries	44,742,737				$ 23		44,742,714
Issuance of common stock for the acquisition of subsidiaries (in shares)					229,450
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts	1,506,196						1,506,196
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts			$ 7,993,885
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts (in shares)			15,656
Accretion of Series B redeemable convertible preferred stock	(4,766,942)						(4,766,942)
Accretion of Series B redeemable convertible preferred stock			$ 4,766,942
Conversion of Series B redeemable convertible preferred stock into common stock	3,479,060				$ 8		3,479,052
Conversion of Series B redeemable convertible preferred stock into common stock (in shares)					82,483
Conversion of Series B redeemable convertible preferred stock into common stock			$ (3,479,060)
Conversion of Series B redeemable convertible preferred stock into common stock (in shares)			(3,479)
Foreign currency translation adjustments	2,997,826									2,997,826
Net loss	(46,425,390)								(46,425,390)
Ending Balance at Dec. 31, 2017	39,395,823				$ 61		121,657,587		(77,684,839)	(4,576,986)
Ending Balance (in shares) at Dec. 31, 2017					608,499
Ending Balance at Dec. 31, 2017			$ 9,281,767
Ending Balance (in shares) at Dec. 31, 2017			12,177
Stock based compensation	762,162						762,162
Stock based compensation (in shares)					322,906
Vesting and accelerated vesting of restricted stock	11,203						11,203
Vesting and accelerated vesting of restricted stock (in shares)					284
Exercises of stock options	$ 22,898				$ 1		22,897
Exercises of stock options (in shares)	9,541				9,540
Conversion of Series B convertible preferred stock into common stock			$ (2,386,285)
Conversion of Series B convertible preferred stock into common stock (in shares)			(2,364)
Accretion of Series B redeemable convertible preferred stock	$ (2,894,885)						(2,894,885)
Accretion of Series B redeemable convertible preferred stock			$ 2,894,885
Conversion of Series B redeemable convertible preferred stock into common stock	9,790,367				$ 50		9,790,317
Conversion of Series B redeemable convertible preferred stock into common stock (in shares)					502,078
Conversion of Series B redeemable convertible preferred stock into common stock			$ (9,790,367)
Conversion of Series B redeemable convertible preferred stock into common stock (in shares)			(9,813)
Redemption of Series B redeemable convertible preferred stock for cash and release of embedded derivative	23,292						23,292
Issuance of common stock for the exchange of warrants	3,433,041				$ 32		3,433,009
Issuance of common stock for the exchange of warrants (in shares)					318,668
Issuance of common stock and units, net of offerings cost	26,735,488	$ 10,667,506			$ 491	$ 241	26,734,997	$ 10,667,265
Issuance of common stock and units, net of offering costs (in shares)					4,916,263	2,400,000
Foreign currency translation adjustments	(463,177)									(463,177)
Net loss	(39,171,152)								(39,171,152)
Ending Balance at Dec. 31, 2018	$ 48,312,566				$ 876		$ 170,207,844		$ (116,855,991)	$ (5,040,163)
Ending Balance (in shares) at Dec. 31, 2018					9,078,238
Ending Balance (in shares) at Dec. 31, 2018			0